Abbvie as competitionAbbvie's CEO hasn't turned the juice on Allergan (a company ABBV bought last year) and he's very competitive. When he turns it on, it will hurt EVNC. Be careful with RVNC. He wishes he liked Revance more. He knows this group (aesthetics) and Abbvie produces the popular Botox.
Your Watchlist
Add stocks to watchlist to monitor them daily and get important alerts.
There's demand for products to improve skin care and appearance, because people want to look good.